Heart Diseases

1
Pipeline Programs
10
Companies
9
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 8 programs with unclassified modality

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Microvascular Therapeutics
1 program
1
EchocardiogramPhase 1/21 trial
Active Trials
NCT03882359CompletedEst. May 2025
Rhythm Pharmaceuticals
2 programs
Bi-plane fluoroscopyN/A1 trial
Implantable Cardioverter DefibrillatorN/A1 trial
Active Trials
NCT03941275Completed51Est. Nov 2021
NCT00328705Completed65Est. Jan 2007
Biotronik
BiotronikGermany - Berlin
1 program
3-channel Holter ECG recordingN/A1 trial
Active Trials
NCT04243070Terminated89Est. Jul 2022
Abbott
AbbottABBOTT PARK, IL
1 program
Amplatzer™ Occlusion DevicesN/A1 trial
Active Trials
NCT06590467Recruiting2,500Est. Nov 2039
Elutia
ElutiaSILVER SPRING, MD
1 program
CanGarooN/A1 trial
Active Trials
NCT04299282WithdrawnEst. Mar 2022
Sensydia
SensydiaCA - Los Angeles
1 program
Cardiac Performance SystemN/A1 trial
Active Trials
NCT05104307Completed79Est. Jan 2024
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
Intervention GroupN/A1 trial
Active Trials
NCT00985179Completed1,000Est. Mar 2012
M&
Merck & Co.RAHWAY, NJ
1 program
SimvastatinN/ASmall Molecule1 trial
Active Trials
NCT00125060Completed72Est. Apr 2004

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Microvascular TherapeuticsEchocardiogram
AbbottAmplatzer™ Occlusion Devices
SensydiaCardiac Performance System
ElutiaCanGaroo
Biotronik3-channel Holter ECG recording
Rhythm PharmaceuticalsBi-plane fluoroscopy
Boehringer IngelheimIntervention Group
Rhythm PharmaceuticalsImplantable Cardioverter Defibrillator
Merck & Co.Simvastatin

Clinical Trials (9)

Total enrollment: 3,856 patients across 9 trials

NCT03882359Microvascular TherapeuticsEchocardiogram

An Ascending Dose Comparison of MVT-100 to Definity in Healthy Volunteers

Start: Apr 2019Est. completion: May 2025
Phase 1/2Completed
NCT06590467AbbottAmplatzer™ Occlusion Devices

Abbott Structural Heart Device Registry

Start: Aug 2024Est. completion: Nov 20392,500 patients
N/ARecruiting
NCT05104307SensydiaCardiac Performance System

Echocardiogram and Cardiac Performance System (CPS) Ejection Fraction Validation Study

Start: Nov 2021Est. completion: Jan 202479 patients
N/ACompleted
NCT04299282ElutiaCanGaroo

CIED Implantation in Low BMI Patients

Start: Jun 2021Est. completion: Mar 2022
N/AWithdrawn
NCT04243070Biotronik3-channel Holter ECG recording

BIO|CONCEPT.ECG-Library (Collection of ECG Signals for Development of Algorithms)

Start: Mar 2020Est. completion: Jul 202289 patients
N/ATerminated
NCT03941275Rhythm PharmaceuticalsBi-plane fluoroscopy

SelectSecure 3830 Lead Imaging

Start: May 2019Est. completion: Nov 202151 patients
N/ACompleted
NCT00985179Boehringer IngelheimIntervention Group

Increasing Vitamin Intake and Physical Activity

Start: Oct 2009Est. completion: Mar 20121,000 patients
N/ACompleted
NCT00328705Rhythm PharmaceuticalsImplantable Cardioverter Defibrillator

D2-EPG Study: Evaluation of New Sensing Circuitry and Capture Management

Start: May 2006Est. completion: Jan 200765 patients
N/ACompleted
NCT00125060Merck & Co.Simvastatin

Transesophageal Magnetic Resonance Imaging (MRI) in Conjunction With Lipid Lowering Measures

Start: Aug 2000Est. completion: Apr 200472 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 3,856 patients
10 companies competing in this space